6/26/2025

Incyte stock popped Thursday after the company's board appointed Bill Meury as its new CEO, replacing Herve Hoppenot, who is retiring.

Source: Yahoo

6/26/2025

WILMINGTON, Del., June 26, 2025--Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire

Source: Yahoo

6/26/2025

Incyte announced that the Company?s Board of Directors has unanimously appointed Bill Meury as Chief Executive Officer , effective immediately. Bill Meury succeeds Hervé Hoppenot who will retire from...

Source: Finnhub

6/26/2025

Incyte Corporation announced that the Company?s Board of Directors has unanimously appointed Bill Meury as President and a member of the Company?s Board of Directors, effective immediately. Bill Meury...

Source: Finnhub

6/24/2025

Incyte has underperformed relative to its biotech peers over the past year, though Wall Street analysts maintain a cautiously optimistic view on the stock’s outlook.

Source: Yahoo

6/23/2025

FDA extends review of Incyte's ruxolitinib cream for children with atopic dermatitis, delaying decision to September 2025.

Source: Yahoo

6/23/2025

WILMINGTON, Del. - Incyte today announced that the U.S. Food and Drug Administration has extended the review period for the supplemental New Drug Application for ruxolitinib cream ), a topical...

Source: Finnhub

6/23/2025

Discover why Genmab A/S stands out as a high-margin biotech with strong partnerships, robust growth prospects, and undervalued metrics. Click for more on GMAB.

Source: SeekingAlpha

6/23/2025

Incyte’s first quarter was marked by significant commercial momentum and robust top-line growth, leading to a positive market reaction. Management attributed the results to strong demand for Jakafi and Opselura, the initial sales contribution from recently launched Niktimvo, and continued expansion in dermatology and hematology-oncology portfolios. CEO Herve Hoppenot emphasized that “Q1 2025 puts us on a great trajectory for long-term growth with the continuous expansion of Apteloa, successful l

Source: Yahoo

6/23/2025

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Regeneron (NASDAQ:REGN) and its peers.

Source: Yahoo

6/20/2025

WILMINGTON, Del., June 20, 2025--Update on FDA Review of Ruxolitinib Cream (Opzelura) for Children Ages 2-11 with Atopic Dermatitis

Source: Yahoo

6/20/2025

Incyte Corporation (NASDAQ:INCY) is one of the 10 biotech stocks screaming a buy. On June 17, Incyte was a big mover in the market, announcing the signing of a strategic partnership with Netherlands QIAGEN N.V. QGEN. The two are coming together to enhance the development of a novel diagnostic panel to support investigational treatments for […]

Source: Yahoo

6/20/2025

By Dean Seal Incyte said federal regulators have extended the review period for evaluating its Opzelura cream as a treatment for moderate atopic dermatitis in children aged 2 to 11. The...

Source: Finnhub

6/19/2025

The FDA approves INCY's Monjuvi in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma, its second approved indication.

Source: Yahoo

6/18/2025

WILMINGTON, Del., June 18, 2025--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).

Source: Yahoo

6/18/2025

By Kelly Cloonan Incyte said it received approval from the Food and Drug Administration for monjuvi, in combination with rituximab and lenalidomide, as a treatment for follicular lymphoma. ...

Source: Finnhub

6/17/2025

Baker Brothers’ Q1 2025 portfolio reveals biotech investment trends. See more on their top holdings, stake changes, and high-conviction strategies.

Source: SeekingAlpha

6/17/2025

In recent days, the U.S. stock market has experienced fluctuations as geopolitical tensions in the Middle East and volatile oil prices have influenced investor sentiment. Amid these uncertainties, identifying stocks that may be undervalued could offer potential opportunities for investors seeking to navigate these challenging conditions.

Source: Yahoo

6/17/2025

INCY jumps 5.1% on a global QIAGEN deal to develop a companion diagnostic for its mutCALR-targeting cancer therapy.

Source: Yahoo

6/17/2025

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Deutsche Bank upgraded Cisco (CSCO) to Buy from Hold with a price target of $73, up from $65. The firm sees improved visibility towards “durable” mid-single-digit growth in upcoming years for Cisco, with tailwinds from artificial intelligence, a Campus portfolio refresh, more favorable near-term compet

Source: Yahoo